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Abstract
Background: Adipose-derived stem cells (ADSCs) are emerging as an alternative stem cell source for cell-based
therapies. Recent data suggest that autologous ADSC-enriched micrografting improves the effects of facial
involvement in systemic sclerosis (SSc). We have extensively characterised ADSCs from SSc patients and compared
their phenotype and function to healthy age- and sex-matched control ADSCs.
Methods: ADSCs were isolated and characterised from a cohort of six SSc patients (ADSC-SSc) and were compared
to six healthy age- and sex-matched controls (ADSC-N). Cell surface phenotype lineage commitment was explored
by flow cytometric analysis of mesenchymal and hematopoietic markers and by the capacity to differentiate to
chondrogenic, osteogenic, and adipogenic lineages. Functional activities of ADSCs were assessed by biochemical
and cellular assays for proliferation, metabolism, adhesion, morphology, migration, and invasion.
Results: Upon characterization of ADSC-SSc, we found that there was no alteration in the phenotype or surface antigen
expression compared to healthy matched control ADSCs. We found that the differentiation capacity of ADSC-SSc was
equivalent to that of ADSC-N, and that ADSC-SSc did not display any morphological or adhesive abnormalities. We found
that the proliferation rate and metabolic activity of ADSC-SSc was reduced (p < 0.01). We found that the migration and
invasion capacity of ADSC-SSc was reduced (p < 0.01) compared to healthy matched control ADSCs.
Conclusions: This study provides important findings that can differentially characterise ADSCs from SSc patients. Results
indicate that the surface phenotype and differentiation capacity of ADSCs from SSc patients are identical to healthy
matched ADSCs. While the findings indicate that the proliferation and migration capacity of ADSC-SSc is reduced,
ADSC-SSc are capable of ex-vivo culture and expansion. These findings encourage further investigation into the
understanding by which ADSCs can impact upon tissue fibrosis.
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Background
Systemic sclerosis (SSc), also known as scleroderma, is
an autoimmune connective tissue disease characterised
by microvascular damage, dysregualtion of innate and
adaptive immunity, and generalized fibrosis in the skin
and multiple organs [1]. Skin fibrosis is the hallmark of
this disease. However, the pathological changes in the af-
fected organs, which include the lungs, gastrointestinal
tract, kidneys, and heart, determine the clinical outcome.
In the diffuse cutaneous disease subset, 10-year survival
is 55% [2]. Fibrosis commonly affects the face and
mouth, resulting in tightening of the skin, irreversible
scarring, and retraction of the lips. A resultant narrowed
oral aperture affects dental structure, speech, facial ex-
pression, psychological status, and quality of life [3].
Fibrosis associated with SSc is the result of excessive
extracellular matrix production (notably collagens) by
activated fibroblasts and myofibroblasts, although other
structural cells, endothelial cells, platelets, and immune
cells all contribute to the pathogenesis and progression
of the disease [1]. Transforming growth factor (TGF)-β
is thought to be one of the central dominant activation
factors, while cytokines and autoantibodies are also be-
lieved to play a major role [4].
There is an unmet clinical need for new and innova-
tive therapies to treat fibrotic diseases such as SSc.
Current available therapies are targeted at treating the
life-threatening complications that arise from organ in-
volvement [5]. Recent clinical evidence suggests that
lipotransfer of autologous adipose-derived stem cells
(ADSCs) leads to regression of radiation-induced fibrosis
and other fibrotic conditions, including SSc [6]. We have
previously documented that autologous ADSC-enriched
microfat transplantation is an effective intervention
ameliorating the effects of fibrosis in facial SSc (http://
meeting.aaps1921.org/abstracts/2015/7.cgi). ADSC-based
therapies may offer an attractive therapeutic option to
treat fibrosis in SSc and other fibrotic conditions.
Little is known about the therapeutic capacity and
function of ADSC populations derived from SSc pa-
tients. Previous studies have attempted to characterise
the phenotype of bone marrow-derived mesenchymal
stem cells (BM-MSCs) from patients with autoimmune
diseases. These reports are conflicting. Some studies re-
port that BM-MSCs derived from patients with auto-
immune diseases including rheumatoid arthritis (RA)
and multiple sclerosis (MS) display an altered phenotype
compared to their healthy counterparts, while others re-
port that BM-MSCs retain their phenotypic properties
[7–10]. BM-MSCs isolated from SSc patients display an
altered phenotype when assessed for endothelial cell dif-
ferentiation and angiogenesis [11–14]. However, our
knowledge of the phenotype and properties of ADSCs in
SSc patients is extremely limited.
Previous studies have shown perturbed bone marrow
stem cell function in SSc and this may be central to dis-
ease development or progression in the late stage [11–14].
By demonstrating that ADSCs are functionally intact
would perhaps offer the best opportunity for optimal au-
tologous stem cell treatment. The aim of this study was to
characterise ADSCs derived from abdominal donor sites
in a cohort of SSc patients compared to ADSCs derived
from a healthy sex- and age-matched control group. Char-
acterisation of patient-derived ADSCs will aid our under-
standing of the potential advantages and likely impact of
this treatment option in SSc.
Methods
All chemicals were purchased from Sigma Aldrich unless
otherwise stated.
Donor specification
Subcutaneous lipoaspirate from the abdomen was ob-
tained from six females with systemic SSc. The age range
of the patients was 28–40 years (mean age 34 ± 6 years).
An age-matched female cohort of six patients undergo-
ing lipotransfer from the abdomen was used as the
healthy matched controls (average age 34 ± 7 years). The
medications prescribed to each of the participants in this
study are detailed in Additional file 1: Table S1.
Isolation of ADSCs
ADSCs were isolated according to a modified method as
described by Naderi et al. [15]. In brief, after the removal
of fibrous tissue and visible blood vessels, samples were
cut into small pieces (3 mm3) and digested in Dulbecco’s
modified Eagle’s medium/Nutrient Mixture F-12 Ham
(DMEM/F12) containing 300 U/ml crude collagenase II
(Invitrogen, Life Technologies Ltd, Paisley, UK) for
30 min in an incubator (37 °C, 5% CO2). The dispersed
material was filtered successively through 40- and 70-
μm cell strainers (BD Biosciences, Oxford, UK). After
centrifugation (290 × g, 5 min), the ADSC-rich cell prep-
aration formed a pellet at the bottom of the tube. After
red cell lysis the supernatant was removed and the pellet
re-suspended prior to being expanded in culture.
Culture of human ADSCs
Cells were maintained in culture in DMEM/F12 for four
passages at 37 °C in a humidified atmosphere of 5%
CO2. At each subsequent passage, cells were seeded to
sub-confluence in 75 cm2 culture flasks at a seeding
density of 0.4 × 103 cells/cm2 (3 × 104/flask) for 7–10
days. When the cells reached approximately 80% conflu-
ence, subculture was performed through trypsinization.
The cell suspension was centrifuged at 290 × g for 5 min,
the pellet was resuspended, and cells were seeded at 3 ×
104 per 75 cm2 flask.
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Cell proliferation and metabolism
Cell metabolism and proliferation was assessed by alamar
blue and DNA assay, respectively. The commercially avail-
able assay Alamar blue™ (Life Technologies, UK) was used
to assess viability and metabolism. The ADSCs were
seeded in six-well plates at a seeding density of 1 × 103/
cm2 (1 × 104 per well) to assess proliferation and metabol-
ism at different time points including 1, 3, 7, and 14 days.
Alamar blue assay was then performed as per the manu-
facturer’s instructions. Briefly, after 4 h of incubation with
alamar blue dye, 100 μl of media was place into 96-well
plates and fluorescence was measured at excitation and
emission wavelength of 530 and 620 nm using Fluoroskan
Ascent FL (Thermo Labsystems, UK). To assess ADSC
proliferation a Fluorescence Hoechst DNA Quantification
Kit was utilised to quantify the DNA content (Sigma, UK).
The assay was performed using the standardised manufac-
turer’s protocol. The fluorescence was measured with ex-
citation set at 360 nm and emission at 460 nm using
Fluoroskan Ascent FL (Thermo Labsystems) (n = 6).
Flow cytometric analysis
Passage (P)2 ADSCs were used for immunophenotopic
characterisation using flow cytometry. ADSCs were
stained with antibodies for different CD antigens and
HLA-DR (Macs Quant Mitenyl Biotec): (antibodies were
not diluted) CD14-Viogreen, Anti-HLA-DR-PerCP-
Vio700, CD34-Vioblue, CD19-APC-Vio770, CD73-PE,
CD90-FITC, and CD105-APC. The antibody isotope was
used as controls as per the manufacturer’s instructions
(Mitenyl Biotec). Data acquisition was performed with
MacsQuant Analyser 10 and data were analysed using
Macs quant analysis software (n = 6).
Adipose stem cell differentiation
Adipose stem cells were differentiated to adipogenic,
chondrogenic, and osteogenic lineages according to Guasti
et al. [16].
Adipogenic differentiation: quantification
ADSCs were cultured to confluence for 3 days and then
incubated with a medium containing DMEM, 10% fetal
bovine serum (FBS), 10 ng/ml insulin, 500 mM 3-
isobutyl-1-methylxanthine, 1 mM dexamethasone, and
1 mM rosiglitazone. After 3 weeks, cells were fixed with
4% paraformaldehyde (PFA), washed with 60% isopropa-
nol for 5 min, and stained with Oil Red O (0.25% wt/vol)
for 10 min. After staining, cells were washed several times
with H2O. For quantification, the dye was extracted with
100% isopropanol for 30 min at room temperature.
Optical density at 495 nm was determined with a plate
reader (Bio-Rad, Hercules, CA; http://www.bio-rad.com).
Fold-change was calculated by using untreated controls as
a reference (n = 6).
Chondrogenic differentiation: quantification
Confluent ADSCs were incubated in a medium containing
DMEM, 10% FBS, 0.1 μM dexamethasone, 10 ng/ml
TGF-β1 (R&D Systems, UK), insulin-transferrin-selenium
(ITS) (Life Technologies), and 50 μg/ml ascorbate. After
3 weeks, cells were fixed in 4% PFA, rinsed with 0.1 N
HCl for 5 min and stained with Alcian Blue (1% in 0.1 N
HCl). For quantification, the dye was extracted with 6 M
guanidine hydrochloride overnight at room temperature,
and optical density at 595 nm was determined. Fold-
change was calculated by using untreated controls as a
reference (n = 6).
Osteogenic differentiation: quantification
Confluent cells were incubated in a medium containing
DMEM, 10% FBS, 0.1 μM dexamethasone, 100 μg/ml as-
corbate, and 10 mM β-glycerophosphate. After 3 weeks,
cells were fixed in ice-cold 70% ethanol for 1 h, washed
with H2O, and stained with 1% Alizarin Red. For quantifi-
cation, stained cells were incubated with 10% acetic acid for
30 min at room temperature, scraped, transferred to 1.5-ml
vials, and heated at 85 °C for 10 min. Debris was eliminated
by centrifugation and the optical density of the superna-
tants was measured at 405 nm. Fold-change was calculated
by using the untreated controls as a reference (n = 6).
Reverse transcription-polymerase chain reaction and
quantitative real-time polymerase chain reaction
RNA was extracted from cells using Trizol (Life Tech-
nologies) according to the manufacturer’s protocol. All
cells were examined after 3 weeks of culture as described
above. RNA was isolated by phenol extraction and
ethanol precipitation. One microgram of RNA was then
reverse transcribed with Moloney murine leukemia virus
reverse transcriptase (Promega, Madison, WI; http://
www.promega.com). The resultant cDNA was amplified
using GoTaq (Promega; Applied Biosystems, Foster City,
CA; http://www.appliedbiosystems.com). mRNA was quan-
tified by real-time quantitative polymerase chain reaction
with the Prism 7500 sequence detection system (Applied
Biosystems) and the QuantiTect SYBR Green PCR Kit
(Qiagen, Hilden, Germany; http://www1.qiagen.com) fol-
lowing the manufacturers’ instructions. Gene expression
data were normalized using GAPDH as a reference (n = 3).
The osteogenic genes collagen type 1 (ColI), alkaline
phosphatase (ALP), and osteocalcin (OC) were eva-
luated. The chondrogenic genes aggrecan (Agg) and
collagen type II (ColII) were examined. The adipogenic
genes fatty acid binding protein 4 (FABP4), peroxisome
proliferator-activated receptor gamma (PPARγ), CCA
AT/enhancer binding protein alpha (C/EBBPα), and
lipoprotein lipase (LPL) were investigated.
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Cell morphology and adhesion
To study ADSC morphology between P1 and P4, immuno-
cytochemistry staining was carried out following 24 h of
culture. Firstly, the media was removed from the 24 wells
and the cells were washed with phosphate-buffered saline
(PBS) three times. Following this, the cells were fixed with
4% (w/v) PFA in pre-warmed PBS at 37 °C for 10–15 min.
Cells were then washed with 0.1% Tween 20 three times,
followed by addition of 0.1% triton X100 for 5 min to im-
prove permeability. The cells were then stained with
Rhodamine Phalloidin dye at 1:40 (diluted in 1000 μl
methanol) in PBS for 40 min. Cells were then washed three
times and mounted onto slides with DAPI to stain the nu-
clei. The cells were visualized under fluorescence micros-
copy (EVOS) at 40× magnification (n = 6). Cell morphology
was carried out using ImageJ software; five random fields of
view of four cells were identified and assessed (n = 20). To
assess ADSC adhesion, the number of cells attached was
assessed over a 24-h time period using a Fluroscence
Hoechst DNA Quantification Kit to quantify DNA content
(Sigma, Gillingham, UK). The assay was performed as per
the manufacturer’s instructions. The fluorescence was mea-
sured with excitation set at 360 nm and emission at
460 nm using Fluoroskan Ascent FL (Thermo Labsystems).
Migration assay
In order to determine the migratory capacity of ADSCs, the
QCM 24-Well Colorometric Cell migration Assay (Merk
Millipore) was performed as per the manufacturer’s proto-
col. Briefly, ADSCs were seeded in expansion medium
without FBS at 10,000 cells per insert. The lower well con-
tained expansion medium with 10% FBS. The plate was
then incubated at 37 °C at 5% CO2 for 24 h. After 24 h, the
inserts were transferred into new wells containing 400 μl
cell stain for 20 min. The inserts were then washed with
PBS and the non-migrated cells removed from the interior
with cotton wool swabs. The dried inserts were then trans-
ferred into 200 μl extraction buffer for 15 min. The optical
density was then measured at 560 nm (n = 6).
Invasion assay
The invasion capacities of ADSCs were assessed with a
Cell Invasion Assay (QCM ECMatrix Cell Invasion Assay,
Merck Millipore). ADSCs were seeded in expansion
medium without FBS at 10,000 cells per insert. The lower
well contained expansion medium with 10% FBS. The
plate was then incubated at 37 °C at 5% CO2 for 24 h.
After 24 h, the medium was removed and the non-
invading cells on the interior of the inserts were removed
with cotton wool swabs. The inserts were then transferred
into 500 μl staining solution for 30 min. Inserts were then
washed with PBS and transferred into 200 μl extraction
buffer. The optical density of 200 μl extracted dye was
then measured at 480/520 nm (n = 6).
Statistical analysis
Inter-treatment comparisons were analysed statistically
using one-way analysis of variance (ANOVA) with Tukey
HSD post-hoc analysis (Prism6 Software). The average
and standard deviation (SD) was calculated. Significance
was described as p < 0.05. Graphpad was used for graph-
ically representing data.
Results
Phenotypic characterisation of ADSCs isolated from SSc
patients
Adipose-derived stem cells (ADSCs) were isolated following
liposuction from a cohort of six female SSc patients
(ADSC-SSc). ADSCs were also isolated from a healthy sex-
and age-matched control group of six that were undergoing
lipotransfer from the abdomen (ADSC-N). Flow cytometric
analysis of mesenchymal and hematopoietic markers was
carried out to characterise the phenotype of ADSC-SSc.
Fluorescence-activated cell sorting (FACS) analysis was
performed on ADSC-SSc and ADSC-N at P2 (Fig. 1a).
ADSC-SSc meet the classification criteria for mesenchymal
stem cells according to the criteria of the International
Society for Cellular Therapy (ISCT) and the International
Federation for Adipose Therapeutics and Science (IFATS)
[17]. ADSC-SSc were positive for CD105, CD90, and CD73,
and negative for hematopoietic markers CD45, CD34,
CD19, CD14, and HLA-DR (Fig. 1b). Using this defined set
of cell surface markers, ADSCs from SSc patients were
phenotypically identical to healthy control ADSCs (Fig. 1b).
The FACS profiles of all of the participants in the study are
detailed in Additional file 2: Table S2.
Comparison of ADSC differentiation capacity from SSc
patients and healthy controls
To further characterise ADSCs from SSc patients, the
capacity of ADSC-SSc to differentiate to adipogenic, chon-
drogenic, and osteogenic lineages was assessed. The differ-
entiation potential of ADSC-SSc was compared to that of
ADSC-N over a 3-week culture period. Supporting previous
work [18], we found that ADSCs from SSc patients exhib-
ited comparable differentiation capacity to ADSCs from
healthy donors (Fig. 2a–c). We found no statistical differ-
ence in osteogenic, adipogenic, or chondrogenic lineages
when assessed by Alizarin Red, Oil Red O and Alcian Blue,
respectively (Fig. 2a–c). The capacity of ADSC-SSc to
differentiate to the osteogenic lineage was further con-
firmed by gene expression analysis. Significantly, although
we found profound increases in the expression of lineage-
specific genes upon differentiation, we found no difference
in the expression profile of the osteogenic genes ColI, ALP,
and OC at day 21 in ADSC-SSc compared to ADSC-N
(Fig. 3a). To confirm differentiation of ADSC-SSc to the
chondrogenic lineage, the expression profile of chondro-
genic genes was evaluated. Again, although we found large
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changes in the expression of the chondrogenic genes Agg
and ColII during cell differentiation, we found no difference
in the expression profile of Agg or ColII in ADSC-SSc com-
pared to ADSC-N at day 21 (Fig. 3b). We also found no dif-
ference in the expression profile of the adipogenic genes
FABP4, PPARγ, C/EBPα, and lipoprotein lipase (LPL) in
ADSC-SSc compared to ADSC-N after 21 days (Fig. 3c).
Comparison of ADSC morphology and adhesion
properties from SSc patients and healthy controls
To further investigate the properties of ADSCs from SSc
patients, the morphology and adhesion of ADSC-SSc were
compared to healthy control ADSCs. Adhesion properties
play an important role in cell-cell and cell-matrix interac-
tions and are a vital component in aiding immunomodula-
tion and angiogenesis [19]. We found that there was no
statistical difference in the adhesive properties of ADSCs
derived from SSc patients and ADSCs from healthy con-
trols (Fig 4a). The morphology of actively proliferating
ADSC-SSc was analysed at P2. Both ADSC-N and ADSC-
SSc displayed a typical fibroblast-like, spindle-shaped
morphology that is characteristic of ADSCs (Fig. 4b). We
did not observe any morphological abnormalities such as
enlargement, granulation, or vacuoles in ADSC-SSc that
would indicate senescence or apoptosis [20]. ADSCs were
cultured to confluence and up to P4 without any apparent
morphological abnormalities (data not shown). A more de-
tailed investigation of F-actin distribution and bundling
confirmed that ADSC-SSc were morphologically identical
to healthy control ADSCs (Fig 4b). There was no statistical
difference in the spread or size of the ADSC-SSc at P1 to
P4 compared to ADSC-N when measured for circularity
index and cell area (μm2) (Fig. 4c).
Comparison of ADSC proliferation and metabolism from
SSc patients and healthy controls
The proliferative and metabolic properties of ADSC-SSc
were compared to control ADSCs. In contrast to a previous
Fig. 1 Flow cytometric analysis of adipose-derived stem cells from systemic sclerosis patients (ADSC-SSc) and from a healthy age- and sex-matched
control cohort (ADSC-N). ADSCs from SSc patients are phenotypically identical to healthy control ADSCs. a Example of the flow cytometric dot plot,
histogram analysis, and the gating used to obtain percent expression on the surface of ADSC-SSc and ADSC-N at passage 2 (P2). b Summary table dis-
playing the average percentage of antigens for each FACS marker expressed on the surface of the cells. FACS analysis was performed on ADSC-SSc
and ADSC-N at P2. FACS analysis was performed for mesenchymal markers CD105, CD90, CD73, and hematopoietic markers CD14, CD45, CD34, CD19,
and HLA-DR. SD standard deviation
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report [18], we found the proliferation rate of ADSC-SSc to
be significantly reduced over 14 days compared to control
ADSCs (p < 0.01) (Fig. 5b). A decreased proliferation rate
was detected in ADSC-SSc at all passages from 1 to 4. We
also found that there was significantly reduced metabolic
activity in ADSC-SSc over 14 days at all passages from 1 to
4 compared to ADSC-N (p < 0.01) (Fig. 5a).
Comparison of ADSC migration and invasion from SSc
patients and healthy controls
We found that migration of ADSC-SSc was significantly
reduced compared to control ADSCs (Fig. 6a). Migration
was assessed at 24 h in response to culture medium con-
taining the non-specific chemoattractant, fetal bovine
serum (FBS). Migration of ADSC-SSc was significantly re-
duced at all passages (P1–P4) compared to control ADSCs
(p < 0.01) (Fig. 6a). We also found that invasion of ADSC-
SSc was significantly reduced compared to control ADSCs
(Fig. 6b). Invasion was assessed by ECMatrix Cell Invasion
Assay at 24 h. Invasion of ADSC-SSc was significantly re-
duced at all passages (P1–P4) compared to control ADSCs
(p < 0.01) (Fig. 6b).
Discussion
Systemic sclerosis (SSc) is characterised by abnormalities in
the cutaneous, subcutaneous, and internal organ connect-
ive tissue leading to scarring and fibrosis of affected struc-
tures and also to localized diminution of subcutaneous
adipose tissue in affected sites [1–4]. The disease typically
progresses over time, and distinct clinical and pathological
phases can be identified in many cases. It can be differenti-
ated into limited and diffuse subsets based upon the extent
and severity of skin thickening. In early-stage disease there
is marked fibrosis and thickening of the skin but, at later
stages, the skin may thin and become atrophic. These
changes are especially marked in the forearms and hands
and the face, areas that are almost always affected in both
SSc subsets [21, 22]. The combination of thickening and
Fig. 2 Differentiation capacity of ADSCs from SSc patients. ADSCs from SSc patients have comparable differentiation capacity to healthy control
ADSCs. a Adipogenic differentiation of adipose-derived stem cells from SSc patients (ADSC-SSc; left image) and ADSCs from healthy controls (ADSC-N;
right image) was assessed by Oil Red O staining. Positive Oil Red O staining and fat globules were observed in both ADSC-SSc and ADSC-N at 3 weeks.
Quantitative analysis of Oil Red O staining at optical density of 495 nm (graph on right) determined that there was no difference in the adipogenic
differentiation capacity of ADSC-SSc compared to ADSC-N (10× magnification). b Chondrogenic differentiation of ADSC-SSc (left image) and ADSC-N
(right image) was assessed by Alcian Blue dye. Positive Alcian Blue staining for proteoglycans was observed in both ADSC-SSc and ADSC-N
at 3 weeks. Quantitative analysis of Alcian blue staining at optical density of 595 nm (graph on right) determined that there was no difference in the
chondrogenic differentiation capacity of ADSC-SSc compared to ADSC-N (10× magnification). c Osteogenic differentiation of ADSC-SSc (left image)
and ADSC-N (right image) was assessed by Alizarin Red dye. Positive Alizarin red staining for calcium was observed in both ADSC-SSc and ADSC-N at
3 weeks. Quantitative analysis of Alizarin staining at optical density of 405 nm (graph on right) determined that there was no difference in the
osteogenic differentiation capacity of ADSC-SSc compared to ADSC-N (n = 3) (10× magnification)
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hardening of the skin and tethering to subcutaneous struc-
tures together with loss of fat and muscle affects function
and appearance. The facial involvement is often severe and
has a major impact on quality of life and also function by
reducing the oral aperture and reducing lip bulk and mobil-
ity [3]. Emerging data support a role for adipocyte transdif-
ferentiation in SSc and it seems that lipoatrophy in the
affected sites may in part be due to loss of adipocytes and
defective stem cell function [23, 24]. Thus, it is an attractive
treatment intervention to transfer fat-derived cells from
proximal sites such as the abdominal wall into areas se-
verely affected in SSc to help regenerate the adipose tissue
and potentially restore connective tissue homeostasis. This
is likely to have a much more profound effect if a popula-
tion of stem cells can be introduced that persists and helps
to remodel local connective tissue.
However, it is critical that autologous fat-derived cells
maintain their normal cellular function and, in particular,
that the stem cell phenotype and potential is maintained.
The purpose of the present study was to assess whether
ADSCs from abdominal sites in SSc are similar to those
from matched healthy donors. This is important to permit
autologous fat transfer procedures and provide a plausible
mechanism for effects that appear to be substantial in
some cases and associated with fat regeneration, improved
skin flexibility, and reduced fibrosis together with better
function of associated structures.
We have previously documented that adipose tissue
lipotransfer significantly improves the effect of fibrosis and
mouth function in facial SSc [6]. The effector cell or mech-
anism that is responsible for the perceived reversal of fibro-
sis is not yet known. Adipose-derived stem cells (ADSCs)
are easily derived from adipose tissue [25]. The immuno-
modulatory and angiogenic effects of ADSCs are well
documented, particularly in ischaemic diseases [26, 27]. It
has also been suggested that ADSCs have anti-fibrotic
properties through secretion of anti-fibrotic factors such as
interferon (IFN)γ and matrix metalloproteinases and by
decreasing pro-fibrotic factors such as TGF-β [28–31].
However, little is known about the therapeutic potential of
ADSCs from SSc patients. The present study aimed to iso-
late, culture, and characterise ADSCs from a cohort of SSc
patients (ADSC-SSc) that were undergoing lipotransfer
treatment for the effects of facial SSc. The phenotype and
potential of ADSC-SSc was compared to ADSC-N that
were isolated from a cohort of healthy sex- and age-
matched controls. We found no difference in the pheno-
type or tri-lineage potential of ADSC-SSc compared to
ADSC-N. We did, however, find differences in the proper-
ties of ADSC-SSc compared to ADSC-N.
Adipose-derived stem cells display remarkable plasti-
city and undergo profound changes in phenotype during
differentiation and exposure to environmental cues [32].
We found that the phenotype and surface antigen ex-
pression of patient-derived ADSC-SSc was not altered
compared to ADSC-N (Fig 1a and b). Supporting this,
we found that the differentiation capacity of ADSC-SSc
was unchanged (Figs. 2 and 3). To date, only one study
Fig. 3 Quantitative RT-PCR analysis of osteogenic-, chondrogenic-, and adipogenic-specific genes expressed in ADSCs from SSc patients. Adipose-derived
stem cells from systemic sclerosis patients (ADSC-SSc) have a similar gene expression profile following differentiation when compared to healthy control
ADSCs (ADSC-N). a Fold-change in expression of the osteogenic genes collagen type 1 (ColI), alkaline phosphatase (ALP), and osteocalcin (OC) in ADSC-SSc
and ADSC-N. b Fold-change in gene expression of the chondrogenic genes aggrecan (Agg) and collagen type II (ColII) in ADSC-SSc and ADSC-N. c Fold-
change in gene expression of the adipogenic genes fatty acid binding protein 4 (FABP4), peroxisome proliferator-activated receptor gamma (PPARγ),
CCAAT/enhancer binding protein alpha (C/EBBPα), and lipoprotein lipase (LPL) in ADSC-SSc and ADSC-N. Gene expression profiling was carried out at
3 weeks following differentiation. Fold change was normalised to GAPDH (n=3)
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has characterised ADSCs from SSc patients [18]. Scuderi
et al. similarly found that ADSCs from SSc patients were
capable of differentiating towards adipogenic, osteogenic,
and chondrogenic lineages [18].
Previous studies have reported that bone marrow stem
cell populations from SSc patients may display early senes-
cence [11, 13]. We did not find evidence of senescence in
our abdominal-derived ADSCs. We did not detect any
morphological abnormalities such as enlargement or cyto-
plasmic granules or vacuoles (Fig. 4b), no alteration in their
adhesive properties (Fig. 4a), and, significantly, no differ-
ence in their differentiation capacity (Figs. 2 and 3), all of
which would indicate a senescent phenotype [20]. Our find-
ings provide evidence that ADSC-SSc are phenotypically
identical to healthy matched ADSCs and can be cultured
ex vivo in sufficient numbers for autologous therapeutic
options. This difference may reflect the origin of the stem
cells. It seems likely that peripheral blood or bone marrow
reflect altered systemic processes in an immune-mediated
disease that are not a feature of adipose-defined cells. In
addition, the ability to harvest from sites that are less
affected in SSc may be a key factor.
While our findings report that the phenotype and tri-
lineage potential of ADSCs from SSc patients was main-
tained, we found that the proliferation rate and metabolic
activity of ADSC-SSc was decreased (Fig. 5). This is in
contrast to the previous report from Scuderi et al. [18].
Additionally, we found that the migration and invasion
potential of ADSCs from SSc patients was reduced (Fig. 6a
and b). Our study differed in two ways. Firstly, the patient
group used in our study was a uniform patient cohort. All
of the patients presented with diffuse cutaneous systemic
sclerosis involving acute fibrosis of the skin and organ
involvement. Secondly, ADSC-SSc in our study were com-
pared to ADSCs from a cohort of healthy age- and sex-
matched controls. It may be postulated that the severity
and systemic nature of the disease presented in this pa-
tient cohort affects some of the properties of ADSC-SSc.
The ability of endogenous stem cells to migrate and in-
vade is central to their repair response [33]. It is not yet
known whether a reduced capacity of endogenous SSc-
ADSC populations to migrate impacts the pathology or
progression of SSc. Local transplantation of autologous
ADSC-SSc creates depots of cells, reducing the need to
migrate and home through a compromised vascular sys-
tem. Local transplantation also facilitates cell-cell contact
and paracrine signalling that are essential for immunomo-
dulation and an angiogenic response [34–36]. Our
previous study demonstrates that local transplantation of
autologous ADSC-SSc by lipotransfer induces a thera-
peutic response [6], while several other studies have
reported that SSc-BM-MSCs maintain some of their
immunosuppressive and angiogenic properties [9, 13, 37].
This supports the use of ADSC-SSc as an autologous
Fig. 4 Analysis of the morphology and adhesion properties of ADSCs from SSc patients. There was no alteration in the adhesive properties or the
morphology of adipose-derived stem cells from systemic sclerosis patients (ADSC-SSc) compared to healthy control ADSCs (ADSC-N). a DNA quantification
assay was carried out to determine the number of cells adhering to tissue culture plastic 24 h after seeding. Adhesion of ADSCs was assessed at passage 1
(P1) to P4. There was no statistical difference in the number of cells that adhered between ADSC-SSc and ADSC-N (n= 6). b Representative bright field im-
ages of ADSC-N at passage 2 (top left panel) and SSc-ADSC s at passage 2 (top right panel) (10× magnification). Representative images of Rhodamine Phal-
loidin staining of F-actin in ADSC-N at passage 2 (bottom left panel) and ADSC-SSc at passage 2 (bottom right panel) (40× magnification). Cells were
counter-stained with DAPI to visualize DNA. Scale bars= 50 μm. c Cell area (left graph) and circularity index (right graph) of ADSC-SSc and ADSC-N at P1 to
P4 was assessed 24 h after seeding using image J software (n= 20). Statistical significance was calculated using unpaired t test
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therapy despite any disease-induced alteration of cellular
properties.
This study assessed the ability of ADSC-SSc to be ex-
panded in culture for therapeutic purposes. Similarly, we
evaluated the phenotype and properties of ADSC-SSc in
vitro at P2 to P4. Other groups have also characterised
ADSCs at P2 and P3 [18]. Prior to P2, ADSC prepara-
tions are not a homogenous population and display a dy-
namic phenotype that changes during culture [38].
Depending on culture conditions, ADSCs in P2 or P3
are morphologically a homogenous population of fibro-
blastoid cells and, due to the artificial environment, will
lose the expression of certain surface markers including
CD34 that is used to identify ADSCs in situ and after a
short culture time [38]. While it is important to charac-
terise these cells as a homogeneous population, as we
have done in this study, it will also be important to char-
acterise the phenotype and properties of ADSC-SSc at
P0 to identify any differences in surface marker expres-
sion prior to expansion in vitro. Quantification of SSc-
ADSC yield at P0 will also provide important informa-
tion that will aid in the enhancement of autologous
ADSC therapy for systemic sclerosis patients. Future
work will focus on evaluating the function of ADSC-SSc
compared to ADSC-N. Secretome analysis and patient-
matched co-culture studies will provide a plausible
mechanism for the anti-fibrotic and restorative effects of
autologous lipotransfer in SSc patients.
Several studies have shown that stem cells, both adipose-
and bone marrow-derived, may allow for the reversal of fi-
brosis. Adipose tissue is an attractive stem cell source due to
a higher yield compared to bone marrow, greater abundance,
and involving a less invasive and painful harvesting procedure
[21, 39, 40]. ADSCs have demonstrated superior therapeutic
potential to BM-MSCs [41, 42]. Their immunomodulatory
function and angiogenic properties, as well as promising clin-
ical effects, suggests that ADSCs may offer a treatment op-
tion for several types of fibrotic diseases [42–44].
Conclusions
Our findings confirm that ADSCs from the abdomen of
SSc patients are phenotypically indistinguishable from
similar cells isolated from healthy controls and can be ex-
panded in culture for autologous therapeutic options. These
findings support the feasibility of treatment approaches that
Fig. 5 Analysis of the proliferative and metabolic properties of ADSCs
derived from SSc patients. Proliferation and metabolism of adipose-
derived stem cells from systemic sclerosis patients (ADSC-SSc) was
decreased over 14 days compared to healthy control ADSCs (ADSC-N).
a Cell metabolism was assessed by the Alamar blue assay on days 1, 3,
7, and 14. Cells were assessed at passage 1 (P1) to P4. ADSC-SSc
displayed significantly less metabolic activity on days 3, 7, and 14 at all
passages assessed (p < 0.01) (n = 6). b Cell proliferation was assessed by
DNA quantification on days 1, 3, 7, and 14. Cells were assessed at P1 to
P4. ADSC-SSc were significantly less proliferative on days 3, 7, and 14 at
all passages assessed (p < 0.01) (n = 6). **p < 0.01
Fig. 6 Analysis of the migration and invasion potential of ADSCs derived
from SSc patients. Migration and invasion potential of adipose-derived
stem cells from systemic sclerosis patients (ADSC-SSc) was reduced
compared to healthy control ADSCs (ADSC-N) at all passages examined.
a Cell migration was assessed by QCM 24-Well Colorometric Cell
migration Assay. Cells were assessed at passage 1 (P1) to P4. Migration
was assessed at 24 h. Migration of ADSC-SSc was significantly reduced at
P1, P2, and P4 compared to healthy control ADSCs (p< 0.01) (n= 6). b
Cell invasion was assessed by QCM ECMatrix Cell Invasion Assay. Cells
were assessed at P1 to P4. Invasion was assessed at 24 h. Invasion of
ADSC-SSc was significantly reduced at P1, P2, and P4 compared to
healthy control ADSCs (p< 0.015) (n= 6). *p <0.05, **p< 0.01
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transfer these ADSCs into affected sites in SSc and provide
insight into potential mechanisms whereby local anti-
fibrotic effects and disease modification may occur.
Additional files
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Additional file 2: Table S2. Table detailing the FACS profile of ADSCs
of each of the participants in this study. (DOCX 54 kb)
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